Welcome to the UPF Digital Repository

Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial

Show simple item record

dc.contributor.author Bernardino, Jose I.
dc.contributor.author Mocroft, Amanda
dc.contributor.author Wallet, Cedrick
dc.contributor.author de Wit, Stéphane
dc.contributor.author Katlama, Christine
dc.contributor.author Reiss, Peter
dc.contributor.author Mallon, Patrick W.
dc.contributor.author Richert, Laura
dc.contributor.author Molina, Jean-Michel
dc.contributor.author Knobel Freud, Hernando
dc.contributor.author Morlat, Philippe
dc.contributor.author Babiker, Abdel
dc.contributor.author Pozniac, Anton
dc.contributor.author Raffi, Francois
dc.contributor.author Arribas, José Ramón
dc.contributor.author NEAT001/ANRS143 Trial Study Group
dc.date.accessioned 2019-07-11T06:18:07Z
dc.date.available 2019-07-11T06:18:07Z
dc.date.issued 2019
dc.identifier.citation Bernardino JI, Mocroft A, Wallet C, de Wit S, Katlama C, Reiss P. et al. Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial. PLoS One. 2019 Jan 28;14(1):e0209911. DOI: 10.1371/journal.pone.0209911
dc.identifier.issn 1932-6203
dc.identifier.uri http://hdl.handle.net/10230/41981
dc.description.abstract BACKGROUND: Comparison of changes in body composition, adipokines and inflammatory markers after initial therapy with a nucleos(t)ide reverse transcriptase inhibitor (N(t)RTI)- sparing or containing regimen are scarce. DESIGN: Randomised Clinical Trial. METHODS: This is the body composition substudy of NEAT 001/ANRS 143, a randomised trial comparing darunavir/ritonavir (DRV/r) plus either raltegravir (RAL) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 805 ART naïve HIV-infected adults. The primary endpoint was percentage change in limb fat at week 96. Secondary endpoints were associations among these changes and metabolic markers (IL-6, insulin, leptin, adiponectin, FGF-23). RESULTS: 126 subjects (61 DRV/r + RAL and 65 DRV/r + TDF/FTC) were included. The rate of change in BMI between groups for RAL versus TDF/FTC at week 96 was 1.5% per 48-week period (p = 0.015). The rate of change in limb fat mass, trunk fat mass, total body fat and total lean mass was for RAL versus TDF/FTC at week 96 was 2.5% (p = 0.38), 7.3% ((p = 0.021), 4.9% (p = 0.061) and 1.3% (p = 0.12) respectively. Baseline insulin and leptin levels were correlated with baseline limb fat and trunk fat mass [r = 0.31 (p = 0.0043)/r = 0.28 (p = 0.0011) for limb fat, and r = 0.63 (p<0.0001)/r = 0.50(p<0.0001) for trunk fat]. After adjustment, a 10% faster increase in leptin between baseline and week 48 was associated with a more rapid increase in limb fat at week 48 (0.5% per 48 weeks, p<0.001), total body fat mass (0.6% per 48 weeks, p<0.001), and trunk fat mass (0.3% per 48 weeks, p = 0.0026). CONCLUSIONS: After week 96 a N(t)RTI sparing regimen of DRV/r + RAL produced a numerically greater percentage increase in body composition variables with only change in trunk fat mass and BMI being significant.
dc.description.sponsorship NEAT is a project funded to the Instituto Superiori di Sanitá-Rome, by the European Union under the Sixth Framework Programme, project number LSHP-CT-2006-037570. This analysis was also partially funded by a grant from the Ministerio de Sanidad y Asuntos Sociales de España (2009/TRA-054). The trial was also supported by Gilead Sciences, Janssen Pharmaceuticals, and Merck Laboratories, and the French National Institute for Health and Medical Research-France Recherche Nord&Sud SIDA-HIV Hépatites (Inserm-ANRS) is the sponsor and a funder of the trial.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Public Library of Science (PLoS)
dc.rights copyright © 2019 Bernardino et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, https://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject.other Sida -- Tractament
dc.subject.other Cos humà -- Composició
dc.title Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1371/journal.pone.0209911
dc.relation.projectID info:eu-repo/grantAgreement/EC/FP6/037570
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking